# US 11,439,703 B2 · Enhanced immune response in porcine species

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,439,703 B2
- Document ID: US11439703B2
- Status: Granted
- Kind: B2
- Application number: 15/748,444
- Filed: 2016-07-28
- Published: 2018-11-15
- Granted: 2022-09-13
- Earliest claimed: 2015-07-31
- Assignees: Elanco US Inc.
- Applicants: Bayer Animal Health GmbH
- Inventors: Albert Abraham; Jason Nickell; Daniel Keil; Christian Weiss
- Web page: https://patentgrep.com/patent/US11439703B2

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 39/12: Viral antigens
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/14: for RNA viruses
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention generally relates to methods of eliciting an immune response in a porcine species subject. In particular, an immunomodulator composition is used to induce an immune response to enhance the subject's ability to fight infectious pathogens.

## Claims

### Claim 1

A method of treating an infection in a recipient food production swine comprising administering an effective amount of an immunomodulator composition to the food production swine, wherein the immunomodulator composition comprises: (a) a nucleic acid sequence having at least 94% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 4, wherein the nucleic acid sequences comprises at least 280 CpG dinucleotides; and (b) a cationic liposome delivery vehicle, wherein the cationic liposome delivery vehicle comprises pairs of lipids selected from the group consisting of N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) and cholesterol; N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTAP) and cholesterol; 1-[2-(oleoyloxy)ethyl]-2-oleyl-3-(2-hydroxyethyl) imidazolinium chloride (DOTIM) and cholesterol; and dimethyldioctadecylammonium bromide (DDAB) and cholesterol;
wherein the immunomodulator composition further comprises or is administered in combination with an immunogen derived from an infectious agent causing the infection, and wherein an immune response to the immunogen is increased in the food production swine with the combination as compared to the immune response in the food production swine elicited with the immunogen by itself.

### Claim 2 (depends on 1)

The method of claim 1, wherein the administration is before exposure to the infectious agent comprising the immunogen.

### Claim 3 (depends on 1)

The method of claim 1, wherein the administration is after exposure to the infectious agent comprising the immunogen.

### Claim 4 (depends on 1)

The method of claim 1, wherein the immunogen is comprised in a vaccine.

### Claim 5 (depends on 1)

The method of claim 1, wherein the immunomodulator composition further comprises a pharmaceutically acceptable carrier.

### Claim 6 (depends on 4)

The method of claim 4, wherein the vaccine is a Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccine or Escherichia coli vaccine.

### Claim 7 (depends on 1)

The method of claim 1, wherein the immunomodulator composition is administered intramuscularly in a single dose.

### Claim 8 (depends on 1)

The method of claim 1, wherein the immunogen is derived from Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) or Escherichia coli.

### Claim 9 (depends on 8)

The method of claim 8, wherein the immunogen is derived from PRRSV.